Every quarter we read National Pension Service headcount and company filings for Korean biohealth employers, and we look in depth at the hiring questions companies ask us most.
The Q4 people and filings review is due in late December
At quarter end we read the change in National Pension Service members by company type together with the companies' filings on DART, Korea's disclosure system. Below are the members counted so far.
Bar length = memberssmall figure = change over 11 months
Biotech16 companies8,981+248
CRO1 company337+7
Pharma29 companies27,412+10
CDMO & bioprocess6 companies8,694+742
Medtech & diagnostics1 company626−28
46,050National Pension Service members, Aug 2026 · 53 companies
+979Change over 11 months · +2.2% · Sept 2025 → Aug 2026 · 53 companies counted · mergers and bulk transfers excluded
Source: National Pension Service workplace register (data.go.kr) · Aug 2026 register · the register is published monthly; every Sunday we check for a new one and rebuild these pages, so figures stay the same until the next month's register is out.
Company analysis
Where experience connects
Transitions that repeat across the companies Banseog analyses, and the experience of the people who made them.
Transition map
What needs to move forward?
Explore the transitions that advance a product and those that leave lasting capability inside an organization.
Product & technology transitions
Organizational capability transitions
Same boundary. Different experience.
External assets → Retained capability
Make acquired technology, knowledge or rights something the organization can use again.
Primary connections · 9 companies · 10 patterns
The question to start withWhat remained inside the company after the collaboration or deal?
The capability to use external partner scale while deciding which technical knowledge, judgment and development responsibility must remain inside as reusable execution capability.
Trace the evidence
Analysis reviewed:
Original sources open in the publisher’s language.
The capability to retain part of clinical, portfolio and development decision ownership after technology transfer or co-development and keep building asset value toward the next inflection point.
Trace the evidence
Analysis reviewed:
Original sources open in the publisher’s language.
The capability to convert externally sourced science into internal research methods, evaluation standards and development know-how that the company can reuse across assets.
Trace the evidence
Analysis reviewed:
Original sources open in the publisher’s language.
The capability to distinguish strategic dependencies, decide what must be owned, and turn technology, facilities, process, quality and organization into repeatable internal capability.
Trace the evidence
Analysis reviewed:
Original sources open in the publisher’s language.
The capability to evaluate external technology, structure responsibilities and rights, and turn it into an asset that internal teams can develop, manufacture and scale.
Trace the evidence
Analysis reviewed:
Original sources open in the publisher’s language.
The capability to integrate acquired platforms, assets or rights across team, data, IP and development governance until they become executable internal pipeline.
Trace the evidence
Analysis reviewed:
Original sources open in the publisher’s language.
The capability to preserve the leverage of external partners while making clinical, commercial and cross-region execution repeatable inside the company itself.
Trace the evidence
Analysis reviewed:
Original sources open in the publisher’s language.
The capability to use partner scale while increasing the economics, rights, manufacturing participation or decision capability retained inside the company.
Trace the evidence
Analysis reviewed:
Original sources open in the publisher’s language.
This is a comparison of Banseog company analyses linked to public evidence. Counts describe this published collection, not hiring volume, salary premiums or a representative sample of the whole market. Watches do not increase the count supporting a comparative analysis.
Existing signals and public-evidence eligibility are checked when the page loads. New company mappings and higher-level interpretations require review; adding a company does not automatically validate a thesis.
Analysis reviewed:
Experience archetypes
Who has made that transition?
These are experience patterns, not job titles, rankings or personality types. A person or company can connect to more than one.
Capability Internalizer
Distinguish the knowledge, execution ability, decision rights or governance left inside.
One question for the interview
What could the internal team do independently after the partner left?
The capability to use external partner scale while deciding which technical knowledge, judgment and development responsibility must remain inside as reusable execution capability.
Trace the evidence
Analysis reviewed:
Original sources open in the publisher’s language.
The capability to retain part of clinical, portfolio and development decision ownership after technology transfer or co-development and keep building asset value toward the next inflection point.
Trace the evidence
Analysis reviewed:
Original sources open in the publisher’s language.
The capability to convert externally sourced science into internal research methods, evaluation standards and development know-how that the company can reuse across assets.
Trace the evidence
Analysis reviewed:
Original sources open in the publisher’s language.
The capability to distinguish strategic dependencies, decide what must be owned, and turn technology, facilities, process, quality and organization into repeatable internal capability.
Trace the evidence
Analysis reviewed:
Original sources open in the publisher’s language.
The capability to evaluate external technology, structure responsibilities and rights, and turn it into an asset that internal teams can develop, manufacture and scale.
Trace the evidence
Analysis reviewed:
Original sources open in the publisher’s language.
The capability to integrate acquired platforms, assets or rights across team, data, IP and development governance until they become executable internal pipeline.
Trace the evidence
Analysis reviewed:
Original sources open in the publisher’s language.
The capability to preserve the leverage of external partners while making clinical, commercial and cross-region execution repeatable inside the company itself.
Trace the evidence
Analysis reviewed:
Original sources open in the publisher’s language.
The capability to use partner scale while increasing the economics, rights, manufacturing participation or decision capability retained inside the company.
Trace the evidence
Analysis reviewed:
Original sources open in the publisher’s language.
The capability to use external partner scale while deciding which technical knowledge, judgment and development responsibility must remain inside as reusable execution capability.
Trace the evidence
Analysis reviewed:
Original sources open in the publisher’s language.
The capability to convert externally sourced science into internal research methods, evaluation standards and development know-how that the company can reuse across assets.
Trace the evidence
Analysis reviewed:
Original sources open in the publisher’s language.
The capability to evaluate external technology, structure responsibilities and rights, and turn it into an asset that internal teams can develop, manufacture and scale.
Trace the evidence
Analysis reviewed:
Original sources open in the publisher’s language.
The capability to integrate acquired platforms, assets or rights across team, data, IP and development governance until they become executable internal pipeline.
Trace the evidence
Analysis reviewed:
Original sources open in the publisher’s language.
The capability to use partner scale while increasing the economics, rights, manufacturing participation or decision capability retained inside the company.
Trace the evidence
Analysis reviewed:
Original sources open in the publisher’s language.
Company-specific watches, not established outcomes. Separate the public starting point from what still needs to happen.
ST Pharm · Proprietary Platform → Productive Asset
Watch whether proprietary RNA platforms become productive assets.
A watch on whether proprietary platform IP moves beyond research into customer adoption, qualified process, manufacturing demand and repeatable productive assets.
Public starting point / The next question
Public starting point
ST Pharm uses SMARTCAP and LNP technology in its mRNA CDMO business and began an AI-based mRNA design and optimization collaboration in 2026.
![Banseog [ biohealth ]](/assets/brand/banseog-biohealth-on-dark.svg?v=20261015){kind=small}